• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Integrating of lipophilic platinum(IV)prodrug into liposomes for cancer therapy on patient-derived xenograft model

    2022-06-20 06:19:46ZioLiQingXuXuefengLinKunyiYuLingLinYangjiaLiuZhiqiangYuTiancaiLiuDixianLuo
    Chinese Chemical Letters 2022年4期

    Zio Li,Qing Xu,Xuefeng Lin,Kunyi Yu,Ling Lin,Yangjia Liu,Zhiqiang Yu,*,Tiancai Liu,Dixian Luo

    a Department of Laboratory Medicine,Huazhong University of Science and Technology Union Shenzhen Hospital(Nanshan Hospital),Shenzhen 518000,China

    b Guangdong Provincial Key Laboratory of New Drug Screening,School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China

    c School of Laboratory Medicine and Biotechnology,Institute of Antibody Engineering,Southern Medical University,Guangzhou 510515,China

    1 These authors contributed equally to this work.

    ABSTRACT Platinum-based anticancer agents such as cisplatin and its analogues are widely used for treating multiple cancers.However,due to the inferior water-solubility,chemoresistance and consequent adverse side effects,their clinical applications are limited.Herein,cholesPt(IV),a lipophilic platinum(IV)prodrug was synthesized for manufacture of CholesPt(IV)-Liposomes aiming to resolve the predefined obstacles encountered by platinum drugs.Following systematic screening,CholesPt(IV)-Liposomes showed a small particle size(105.6 nm),the rapid release of platinum(Pt)ions,and notable apoptosis of cancer cells.In addition,according to the fluidity and safety results of animal experiments in mice,CholesPt(IV)-Liposomes also showed better therapeutic effect,which significantly inhibited the growth of patientderived xenograft tumors of hepatocellular carcinoma with an inhibition ratio of 80.7%,and effectively alleviated the drug toxicity brought by traditional platinum drugs.Overall,this study provides a promising route to enhance the therapeutic efficiency of platinum drugs in cancer treatment.

    Keywords:Lipophilic platinum(IV)prodrug Liposome Cancer therapy Drug delivery Patient-derived xenograft

    Recent years,cancer has become a formidable medical hot issue[1,2].Platinum-based anticancer agents such as cisplatin and its analogues are widely used to treat multiple cancers[3–7].However,the inferior water-solubility,chemoresistance and consequent adverse side effects limit their clinical applications[8–10].Therefore,it is of great clinical significance to develop a novel strategy to improve platinum efficiency and reduce side effects.

    Nanotechnology-based drug delivery systems have been shown to improve the therapeutic efficiency of chemotherapeutics and reduce system toxicity due to their enhanced permeability and retention effect,which are emerging as the next-generation anticancer agents[11–20].As a tempting modality of nanomedicine,liposomes characterized with spherical nano-scaled vesicles from phospholipids(and other lipids),have been intensively explored as drug delivery vehicles with respect to its excellent biocompatibility,capable of avoiding detection by the body’s immune system,specifically,the cells of reticuloendothelial system[21–23].Besides,liposomes are available to facile post chemistry functionalization,such as PEG surface coating(inert in the body)onto liposomes,which entitle prolonged blood retention for improved bioavailability to the targeted tumor[24–26].For example,He and co-workers reported that non-PEGylated formulations were quickly cleared,while non-PEGylated prodrug nanoparticles(PTXS-S-OA/TPGS2kNPs)exhibited persistently high concentrations of PTX in plasma by evading the identification and phagocytosis of reticulo-endothelial system(RES)[27].Nevertheless,the poor molecular affinity of platinum drugs to the lipids imposes diffi-culty to direct incorporation of platinum drugs into the liposomes.To tackle this drawback,we attempted to couple the lipophilic cholesterol to the platinum drugs.Of note,pioneering research advocated the importance of construction of appropriate Pt(IV)prodrugs as rationale alternative to Pt(II)[28–33].In contrast to Pt(II)susceptible to ligand substitution in the extracellular milieu to induce detoxification of Pt(II),the Pt(IV)prodrugs haven been elucidated to impart improved inertness to ligand substitution,consequently lower the extent of platinum sequestration and deactivation en route to the tumor cells.In this respect,we are encouraged to engineer a cisPt(IV)lipophilic prodrug by attaching cisPt(IV)at the terminus of cholesterol[referred as cholesPt(IV)hereafter]for manufacture of liposomes.

    Fig.1.Schematic illustration and characterizations of cholesPt(IV)-functionalized liposome.Liposomes integrated by cholesPt(IV)were prepared by sequential film hydration and extrusion approach.(a)Anchor of cholesPt(IV)into the lipid bilayer of liposome to yield CholesPt(IV)-Liposome.(b)Integration percentage of cholesPt(IV)as a function of varying feed ratios of cholesPt(IV)/lipids.(c)Representative DLS result of cholesPt(IV)integrated liposome at the identified feed ratio of cholesPt(IV)/lipid of 0.4:1.(d)Colloidal stability of CholesPt(IV)-Liposome(at the identified feed ratio of cholesPt(IV)/lipid ratio of 0.4:1).The size derivation of the formulated liposome was monitored by DLS measurement.

    Herein,cholesPt(IV)was synthesized according to a ligation reaction between cisPt(IV)and cholesterol(Scheme S1 in Supporting information).The yielded product was confirmed by exhaustive chemistry characterizations including FT-IR,1H NMR,ESI-MS,HPLC and elemental analysis(Figs.S1–S4 and Table S1 in Supporting information).The obtained cholesPt(IV)molecule was used as supplementary component to integrate with phospholipids of HSPC and PEGylated lipid for preparation of liposome(Fig.1a).A film hydration and membrane extrusion method was adopted to create liposome[34].Aiming for identification of an optimal condition for construction of cholesPt(IV)-functionalized liposomes,the liposome was prepared from constant quantity of phospholipids of HSPC and PEGylated lipid,but varied quantities of cholesPt(IV).The feed ratio of cholesPt(IV)and lipids was varied from 0.2:1 to 1:1.The integration efficiency of cholesPt(IV)into liposomes was quantified by ICP-MS measurement(Fig.1b).Apparently,high integration percentage of cholesPt(IV)could be achieved at relative low feed ratio of cholesPt(IV)/lipids.The total integration quantity calculated by the quantified integration percentage and the total feed quantity of cholesPt(IV),led to identification of an optimal formulation at cholesPt(IV)/lipid feed ratio of 0.4:1 to possess maximal cholesPt(IV)integration.

    The formulated structures were further transferred to dynamic light scattering(DLS)and zeta potential measurement.No marked difference in the size and surface charge was observed for the class of formulated liposomes irrespective of feed ratio of cholesPt(IV)/lipid,as evidenced by comparable diameters(ranging from 100 nm to 140 nm)and zeta potentials(ranging from-22 mV to-27 mV)(Table S2 in Supporting information).The identified liposome at cholesPt(IV)/lipid feed ratio of 0.4:1 was determined to possess an average diameter of 105.6 nm with unimodal polydispersity index of 0.07 by DLS measurement(Fig.1c).TEM of the liposome(0.4:1)also showed the similar formation as DLS(Fig.S5 in Supporting information).Furthermore,excellent colloidal stability of the formulated liposome was confirmed from the observation of constant DLS size over extended incubation(over 10 days)in PBS(Fig.1d).

    Fig.2. In vitro toxicity of diverse platinum formulations of cisPt(IV),cisplatin and CholesPt(IV)-Liposome in A2780 and A2780 DDP cells.Cell viability of A2780(a)and A2780 DDP(b)under treatment of cisPt(IV),cisplatin and cholesPt-NPs for 72 h.The IC50 of cisPt(IV),cisplatin and CholesPt(IV)-Liposome on A2780 and A2780 DDP cells at 72 h were shown in(c).(d)The drug resistance fold of each platinum drug formulation was calculated by the ratio of IC50 at A2780 DDP to IC50 at A2780.

    Prior to the drug potency test,it is important to demonstrate the proposed CholesPt(IV)-Liposome capable of releasing the active Pt(II)drugs inside the cells.Here,we evaluated the drug release rate from liposomes under diverse stimuli(presented inside the cells).Given that the cell interior is characterized as a distinctive reductive compartment(abundant existence of glutathione and ascorbic acids),the conversion of Pt(IV)derivatives to Pt(II)is presumed to be facilitated by means of redox-triggered release of two ligands and regeneration of the active Pt(II).In addition,nano-scaled structures are envisaged to internalize the cell through endocytosis pathway,followed by transfer to acidic endosome[35–37].In view of readily hydrolysis of Pt(IV)particularly in acidic milieu,it could be conjectured that the release of drug from liposome is facilitated in the subcellular endosome compartment.The subsequent investigations approved our speculation that both reductive treatment(ascorbate acid resembling the cell interior)and acidic treatment(pH 5 resembling the endosome pH)could stimulate the drug release.As opposed to negligible drug release at pH 7.4,liposome incubated at pH 5 exhibited markedly accelerated drug release profile.To our interest,liposome under treatment of ascorbate(10 mmol/L)exhibited most appreciable drug release profile(Fig.S6 in Supporting information).These results approved appealing characters of the proposed liposome that managed to preserve the drug payload in the formulation in the extracellular milieu but allow selective intracellular drug release of drug,which apparently is favorable in pursuit of minimized non-specific toxicity and premature drug detoxification.

    Fig.3.Impact of drug resistance on cellular uptake of diverse platinum derivatives.Quantification of intracellular platinum in A2780(a)and A2780 DDP(b)after 2 and 6 h drug incubation with cisplatin,cisPt(IV)and CholesPt(IV)-Liposome.The uptake-reducing index was summarized in(c).The uptake-reducing was defined as the ratio of platinum uptake at A2780 to platinum uptake at A2780 DDP.(d)Cellular uptake activity of CholesPt(IV)-Liposome at 37 and 4 °C.

    To validate the feasibility of the proposed CholesPt(IV)-Liposome in circumventing the drug resistance,a comparative study was conducted on the drug potency of diverse platinum derivatives to two types of human ovarian cancer cells,A2780(cisplatin susceptible cell line)and A2780 DDP(cisplatin resistant cell line).Cisplatin and cisPt(IV)were included as controls[cholesPt(IV)was not included in this study due to its poor solubility).Herein,the cells were treated by platinum drug derivatives at varying concentration for 72 h incubation(Figs.2a and b).The drug potency was assessed by measuring the cell viability relative to the control blank sample.Pertaining to the cisplatin-susceptible cell line of A2780,cisplatin was observed to exert most pronounced potency(IC50:2.7 μmol/L),whose IC50is markedly lower than that of cisPt(IV)(IC50:20.7 μmol/L)and CholesPt(IV)-Liposome(IC50:10.2 μmol/L)(Fig.2c).A plausible reason for the high potency of cisplatin[Pt(II)]over Pt(IV)derivatives should be attributed to the chemistry of Pt(IV)derivatives requiring additional step for activation of Pt(IV).Noteworthy was the significantly elevated drug potency of CholesPt(IV)-Liposome as compared to cisPt(IV).In respect to poor affinity of cisPt(IV)to the lipophilic cell membrane,most likely,the increased drug potency of CholesPt(IV)-Liposome could be accredited to its superior affinity to the cell membrane for promoted cellular uptake.The subsequent quantification of intracellular platinum by ICP-MS for the samples of cell lysis affirmed promoted internalization of CholesPt(IV)-Liposome as compared to cisPt(IV)(Fig.3a).

    Pertaining to cisplatin-resistant cell line of A2780 DDP,CholesPt(IV)-Liposome mediated notable potency,possessing an IC50of 12.6 μmol/L even exceeding the potency of cisplatin(IC5018.6 μmol/L)(Fig.2c).Close observation of the IC50values of cisplatin in A2780 and A2780 DDP identified the drug resistance characters of A2780 DDP substantially curtailed the drug potency of cisplatin,whose IC50was subjected to pronounced rise from 2.7 μmol/L in A2780 to 18.6 μmol/L in A2780 DDP(Fig.2c).The reduced drug potency of cisplatin may be attributable to the characteristic impeded drug internalization implicated in the drug resist cells.Of note,cisplatin is elucidated to translocate to the cell interior either through passive diffusion or active transportation with aids of cell membrane protein(copper transporter 1:Ctr1)[38].Molecular insight identified the reduced expression of Ctr1 protein in the platinum-resistant cells,which hampers the efficiency of the Ctr1-dependent cisplatin internalization.In accordance,quantification of intracellular platinum affirmed remarkably reduced internalization of cisplatin[also cisPt(IV)]at drug-resistant cell line.Particular noteworthy was reduced intracellular cisplatin at 6 h post incubation as compared to that at 2 h(Figs.3a–c),implying the critical impact of platinum-resistant cells,not only feasible of impeding internalization but also capable of prompting efflux of molecular platinum drugs.On the contrary,nanoparticles have been documented to steer an alternative endocytosis pathway rather than Ctr1-mediated transportation.Hence,the cell internalization of CholesPt(IV)-Liposome is envisioned to be unperturbed by the reduced expression of Ctr1 in the drug resistant cells,thereby capable of overcoming the impeded cellular uptake presented by drug resistant cells.Subsequent investigations approved CholesPt(IV)-Liposome capable of overcoming drug resistance,as evidenced by comparable drug potency of CholesPt(IV)-Liposome to A2780 and A2780 DDP,approximate 9.7 μmol/L for A2780 and 11.4 μmol/L for A2780 DDP,respectively(Figs.2c and d).In accordance to comparable IC50value of CholesPt(IV)-Liposome in A2780 and A2780 DDP,CholesPt(IV)-Liposome mediated similar level of cell uptake efficiency,which is in stark contrast to aforementioned cisplatin whose cell uptake efficiency was substantially lowered.These results suggest CholesPt(IV)-Liposome adopted an alternative pathway for cell internalization.CLSM observation for intracellular distribution of internalized CholesPt(IV)-Liposome captured colocalization of CholesPt(IV)-Liposome and endosome,confirmed the proposed CholesPt(IV)-Liposome internalized cell through endocytosis(Fig.S7 in Supporting information).Still,marked reduced cell uptake of CholesPt(IV)-Liposome at 4 °C as compared to 37 °C(Fig.3d),again affirmed CholesPt(IV)-Liposome internalized cells through an energy-dependent endocytosis pathway.Moreover,as opposed to aforementioned distinctive efflux character of A2780 DDP for cisplatin,the intracellular platinum was observed to progressive increase(Fig.3b),suggesting utilization of liposome by means of integration of lipophilic cholesPt(IV)prodrug in liposome could address the impeded cell internalization drawbacks of the molecular drugs encountered in drug resistant cells.

    For a quantitative evaluation of the capacity of proposed system in overcoming the drug resistance(impeded cellular uptake),the uptake-reducing index was calculated by quantification of the ratios of diverse platinum derivatives uptake level at A2780 to the uptake level at A2780 DDP.Higher value of uptake-reducing index stands for the crucial impact of drug resistance on impeding drug internalization.In agreement of drug potency evaluation,cisplatin showed highest uptake-resistance index(Fig.2d),suggesting its drug potency was markedly dwindled by the characters of drug resistant A2780.The molecular drug of cisPt(IV)also showed considerable high uptake resistance index,consistent with the previous claim that the drug resistance is versatile to a wide spectrum of molecular drugs.On the contrary,the uptake reducing index of CholesPt(IV)-Liposome is in proximity of 1,which approved appreciable strategy of manufacture of liposome as drug delivery vehicle to manage the impeded cell uptake schemed by drug resistant cells.

    Similarly,based on IC50values of diverse platinum drugs for A2780 and A2780 DDP(Fig.2c),the drug resistance index[defined by the ratio of IC50obtained for platinum-resistance cell line(A2780 DDP)to the IC50obtained for platinum-susceptible cell line(A2780)](Fig.2d)was calculated to characterize the capacity of diverse platinum drugs in overcoming drug resistance.In principal,lower drug resistance index,particularly approximate to 1(similar drug potency to platinum-susceptible cell line and platinum-resistant cell line),stands for higher capacity in overcoming the drug resistance.Overall,distinctive drug resistance was observed for cisplatin,as evidenced by high drug resistance index of 5(Fig.2d).Considerable drug resistance was also observed for Pt(IV),despite reduced drug resistance index of 2.3(Fig.2d).To our interest,CholesPt(IV)-Liposome afforded appreciable capacity in overcoming the drug resistance,whose drug resistance index is 1.2(Fig.2d).

    Fig.4. In vivo antitumor effects of CholesPt(IV)-Liposome.(a)Tumor growth curves of HCC PDX-bearing mice during the treatment process.(b)Body weight curves of mice.Weight(c)and image(d)of the tumors harvested from mice on day 10.???P <0.001.

    CholesPt(IV)-Liposome displayed stronger cytotoxicity than cisplatin and platinum(IV)at the same concentration(Fig.S8 in Supporting information).Inspired by the results of cytotoxicityin vitro,the antitumor effects of CholesPt(IV)-Liposome were further investigatedin vivo.We established a patient-derived xenograft(PDX)model of hepatocellular carcinoma(HCC)on BALB/c nude mice to reproduce the histological and microenvironmental features of tumor.Although cisplatin showed significant inhibition of tumor growth,the CholesPt(IV)-Liposome exhibited the best antitumor efficacy,with an inhibitory rate of 80.7% compared to the saline group(Figs.4a and d).Notably,the mice treated with cisplatin were observed apparent toxic side effects.In detail,the reduced weights of the mice failed to return to the normal level at the end of treatment.The body weights of CholesPt(IV)-Liposome-treated mice,however,were no apparent changes(Fig.4b).Mice treated with CholesPt(IV)-Liposome had smaller tumors(0.53 ± 0.11 g),which was 1/3 that of tumors from mice received PBS treatment(1.67 ± 0.36 g)(Fig.4c).These results indicate that CholesPt(IV)-Liposome had stronger antitumor efficacy but with lower systemic toxicity.

    Hematoxylin and eosin(H&E),TdT-mediated dUTP Nick-End Labeling(TUNEL)-staining,and immunofluorescence analysis of tumor tissues results revealed that CholesPt(IV)-Liposome could cause more necrosis and apoptosis,as well as damaged DNA strands(Fig.5a),which demonstrated that CholesPt(IV)-Liposome had superior antitumor effects.In addition,there was no obvious histological toxicity in main organs(heart,liver,spleen,lung,and kidney)and blood biochemistry,which indicated the excellent biocompatibility of CholesPt(IV)-Liposome(Fig.5b and Fig.S9 in Supporting information).

    We further explored the antitumor mechanism of CholesPt(IV)-Liposome by western blotting.Compared with cisplatin or platinum(IV),the CholesPt(IV)-Liposome-treated cells exhibited marked up-regulation of apoptosis-related proteins,such as cleaved caspase 3(abbreviated as C-Caspase 3),P53,Bax,as well as decreased anti-apoptosis protein Bcl-2(Figs.6a and b).Compared with cisplatin and platinum(IV),the CholesPt(IV)-Liposome could lead to increased expression of cleaved PARP(abbreviated as CPARP)andγ-H2A.X,which suggested that CholesPt(IV)-Liposome could effectively cause DNA damages(Figs.6c and d).

    Fig.5.Therapeutic efficacy and biocompatibility evaluation of CholesPt(IV)-Liposome on HCC PDX models.(a)H&E staining,immunohistochemistry of TUNEL(brown),and γ-H2A.X(green)analyses of tumor sections.Scale bar:50 μm.(b)Biochemical analysis of serum after the treatments on 10 d.

    Fig.6.Antitumor mechanism investigation of CholesPt(IV)-Liposome.Western blot analysis(a)and quantification(b)of antitumor-associated proteins in HepG2 cells after various treatments.Western blot analysis(c)and quantification(d)of DNA damage related proteins.*P <0.05,**P <0.01,***P <0.001.

    To this end,we demonstrated a valid strategy of coupling Pt(IV)prodrug to a lipophilic cholesterol for fabrication of CholesPt(IV)-Liposome.The subsequent investigations explicated the proposed formulation capable of promoting cell internalization of platinum prodrug.CholesPt(IV)-Liposome possessed a higher cytotoxicity against the cancer cells in comparison with cisplatin.In addition,CholesPt(IV)-Liposome induced a substantial decrease in the size of patient-derived xenograft tumors of hepatocellular carcinoma in mice.Furthermore,CholesPt(IV)-Liposome had lower toxicity to normal organs,revealing it’s good biocompatibility.In view of its appreciable competence in improving platinum efficiency and reducing side effects,the proposed formulation should be emphasized as a worthy strategy in development of potent platinum delivery systems for cancer treatment.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    This work was financially supported by the GDNRC[Guangdong Nature Resource Center](2020)(037),National Natural Science Foundation of China(Nos.81773642,52073139),the Natural Science Foundation of Guangdong Province(No.2019A1515011619),Guangdong Provincial Science and Technology Department(No.2016A030311015),the Key R &D Plan of Chenzhou(No.ZDYF202008),and the Discipline Leader Startup Fund of Huazhong University of Science and Technoloy Union Shenzhen Hospital(No.YN2021002).BABL/c nude mice are used in accordance with the guidelines of ICE for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University Approval Letter for Research Protocol(No.2018240).

    Supplementary materials

    Supplementary material associated with this article can be found,in the online version,at doi:10.1016/j.cclet.2021.10.077.

    蜜桃久久精品国产亚洲av| 青春草亚洲视频在线观看| 亚洲在线观看片| 人人妻人人澡欧美一区二区| 午夜福利视频1000在线观看| 国产免费一级a男人的天堂| 99热6这里只有精品| 国产精品综合久久久久久久免费| 亚州av有码| www日本黄色视频网| 国产麻豆成人av免费视频| 精品一区二区三区人妻视频| 99热全是精品| 美女大奶头视频| 老师上课跳d突然被开到最大视频| 久久精品夜夜夜夜夜久久蜜豆| 成人特级黄色片久久久久久久| 国产午夜精品一二区理论片| 国产亚洲欧美98| 亚洲精品影视一区二区三区av| 国产成人精品婷婷| 大型黄色视频在线免费观看| 波野结衣二区三区在线| 啦啦啦观看免费观看视频高清| 国产亚洲av嫩草精品影院| 欧美性猛交黑人性爽| 2022亚洲国产成人精品| 中文资源天堂在线| 久99久视频精品免费| 一区二区三区免费毛片| 波多野结衣高清作品| 久久久久久九九精品二区国产| 亚洲无线观看免费| 亚洲av电影不卡..在线观看| 天天躁日日操中文字幕| 九色成人免费人妻av| 26uuu在线亚洲综合色| 精品一区二区三区人妻视频| 少妇的逼水好多| 啦啦啦啦在线视频资源| 欧美成人一区二区免费高清观看| 亚洲av一区综合| 免费电影在线观看免费观看| 免费观看a级毛片全部| 久久久久国产网址| 国产av麻豆久久久久久久| 啦啦啦啦在线视频资源| 亚洲人与动物交配视频| 夜夜爽天天搞| 久久人人爽人人爽人人片va| 国产 一区精品| 99久久久亚洲精品蜜臀av| 亚洲av一区综合| 女同久久另类99精品国产91| 久久精品国产亚洲av涩爱 | 性插视频无遮挡在线免费观看| 波多野结衣高清作品| 26uuu在线亚洲综合色| 亚洲国产高清在线一区二区三| 天堂av国产一区二区熟女人妻| 精品人妻一区二区三区麻豆| 男人狂女人下面高潮的视频| 亚洲国产色片| 变态另类丝袜制服| 国产高清激情床上av| 中文字幕av成人在线电影| 日韩,欧美,国产一区二区三区 | 成人性生交大片免费视频hd| 一区二区三区四区激情视频 | a级毛色黄片| 亚洲最大成人手机在线| av卡一久久| 中国国产av一级| 五月玫瑰六月丁香| av免费观看日本| 午夜福利高清视频| 99视频精品全部免费 在线| 国产免费男女视频| 又爽又黄a免费视频| 国产视频内射| 欧美xxxx黑人xx丫x性爽| 听说在线观看完整版免费高清| 国产男人的电影天堂91| av国产免费在线观看| 久久久久久久久久久丰满| 亚洲成a人片在线一区二区| 成人无遮挡网站| 久久热精品热| 日日摸夜夜添夜夜添av毛片| 国产精品久久电影中文字幕| 国产片特级美女逼逼视频| 欧美zozozo另类| 日日摸夜夜添夜夜爱| 午夜精品在线福利| 免费看日本二区| 国产高清三级在线| 亚洲欧美成人精品一区二区| 国产精品一区二区在线观看99 | 听说在线观看完整版免费高清| av卡一久久| 熟女人妻精品中文字幕| 老司机福利观看| 欧美潮喷喷水| 九草在线视频观看| 我的老师免费观看完整版| 亚洲欧美精品专区久久| 男女做爰动态图高潮gif福利片| 有码 亚洲区| av视频在线观看入口| 99久久精品国产国产毛片| 成人鲁丝片一二三区免费| 午夜久久久久精精品| 亚洲无线观看免费| 免费观看在线日韩| av在线观看视频网站免费| 精华霜和精华液先用哪个| 丰满人妻一区二区三区视频av| 我要看日韩黄色一级片| 国产高清有码在线观看视频| 一本久久精品| 日韩高清综合在线| 麻豆乱淫一区二区| 别揉我奶头 嗯啊视频| 成人美女网站在线观看视频| 日韩国内少妇激情av| 特级一级黄色大片| 日本-黄色视频高清免费观看| 欧美日本亚洲视频在线播放| 久久精品国产清高在天天线| 一边亲一边摸免费视频| 美女xxoo啪啪120秒动态图| 97热精品久久久久久| 国产亚洲欧美98| 黄色欧美视频在线观看| 网址你懂的国产日韩在线| 国产女主播在线喷水免费视频网站 | 亚洲电影在线观看av| 日本与韩国留学比较| 美女黄网站色视频| or卡值多少钱| 亚洲精品久久国产高清桃花| 成人无遮挡网站| 韩国av在线不卡| 日本在线视频免费播放| 精品久久久久久久人妻蜜臀av| 国语自产精品视频在线第100页| 日本五十路高清| 3wmmmm亚洲av在线观看| 爱豆传媒免费全集在线观看| 中国国产av一级| 一本久久中文字幕| 午夜激情福利司机影院| 午夜久久久久精精品| 国产伦理片在线播放av一区 | 亚洲成人中文字幕在线播放| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 国产女主播在线喷水免费视频网站 | 性色avwww在线观看| 性欧美人与动物交配| 成人午夜精彩视频在线观看| 日本熟妇午夜| 国产免费一级a男人的天堂| 热99在线观看视频| 国产精品爽爽va在线观看网站| 亚洲最大成人手机在线| 国产精品久久电影中文字幕| 18+在线观看网站| 日本黄大片高清| 久久精品夜夜夜夜夜久久蜜豆| 九九热线精品视视频播放| 一本久久精品| 国产精品永久免费网站| 国产日韩欧美在线精品| 网址你懂的国产日韩在线| 最好的美女福利视频网| 欧美精品国产亚洲| 91在线精品国自产拍蜜月| 国产精品久久久久久精品电影小说 | 国产三级在线视频| 色综合亚洲欧美另类图片| 青青草视频在线视频观看| 国产麻豆成人av免费视频| 国产在视频线在精品| 久久亚洲国产成人精品v| h日本视频在线播放| 日韩精品青青久久久久久| 色噜噜av男人的天堂激情| 激情 狠狠 欧美| 高清毛片免费观看视频网站| 简卡轻食公司| 99久久成人亚洲精品观看| 日韩在线高清观看一区二区三区| 三级国产精品欧美在线观看| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 女人被狂操c到高潮| 亚洲av二区三区四区| 国产精品三级大全| 高清在线视频一区二区三区 | 成人国产麻豆网| 99在线视频只有这里精品首页| 欧美日韩国产亚洲二区| 亚洲18禁久久av| 国产精品久久久久久久久免| 精品人妻偷拍中文字幕| 99riav亚洲国产免费| 日日摸夜夜添夜夜添av毛片| 少妇的逼好多水| 老司机福利观看| 日韩欧美 国产精品| 亚洲aⅴ乱码一区二区在线播放| 欧美一级a爱片免费观看看| 91aial.com中文字幕在线观看| 日韩高清综合在线| 欧美不卡视频在线免费观看| 青青草视频在线视频观看| 十八禁国产超污无遮挡网站| 热99在线观看视频| 欧美色欧美亚洲另类二区| 国产亚洲精品久久久久久毛片| 最近视频中文字幕2019在线8| 久久精品国产鲁丝片午夜精品| 亚洲精品久久久久久婷婷小说 | 一级黄片播放器| .国产精品久久| 国产精品爽爽va在线观看网站| 尤物成人国产欧美一区二区三区| 亚洲成人中文字幕在线播放| 少妇熟女欧美另类| 国产一级毛片七仙女欲春2| а√天堂www在线а√下载| 欧美潮喷喷水| 日韩制服骚丝袜av| 亚洲精品456在线播放app| 午夜福利在线观看免费完整高清在 | 国内精品久久久久精免费| 亚洲精品成人久久久久久| 国产精品一区www在线观看| 国产黄片美女视频| 听说在线观看完整版免费高清| 十八禁国产超污无遮挡网站| 久久婷婷人人爽人人干人人爱| 少妇人妻精品综合一区二区 | 免费人成视频x8x8入口观看| 特级一级黄色大片| 精品久久国产蜜桃| 国产色婷婷99| 亚洲一级一片aⅴ在线观看| 国产亚洲欧美98| 国产免费一级a男人的天堂| 免费人成视频x8x8入口观看| 久久精品国产亚洲av涩爱 | 人妻制服诱惑在线中文字幕| 偷拍熟女少妇极品色| 国产成人a区在线观看| 国产一区二区在线观看日韩| a级毛色黄片| 不卡一级毛片| 日韩欧美精品免费久久| 国产毛片a区久久久久| 国产一区二区在线av高清观看| 午夜福利成人在线免费观看| 久久99蜜桃精品久久| 国产片特级美女逼逼视频| 人人妻人人澡人人爽人人夜夜 | 免费看a级黄色片| 久久午夜亚洲精品久久| 你懂的网址亚洲精品在线观看 | 一级黄片播放器| 亚洲电影在线观看av| 亚洲aⅴ乱码一区二区在线播放| 看黄色毛片网站| 99热只有精品国产| 老师上课跳d突然被开到最大视频| 免费观看a级毛片全部| 狂野欧美白嫩少妇大欣赏| 高清午夜精品一区二区三区 | 日本黄大片高清| 欧美成人a在线观看| 国产伦在线观看视频一区| 精品久久久久久久久av| 国产成人精品一,二区 | 免费人成在线观看视频色| 国产精品久久久久久精品电影| 男人狂女人下面高潮的视频| 久久99蜜桃精品久久| 可以在线观看的亚洲视频| 小说图片视频综合网站| 国产高清有码在线观看视频| 两性午夜刺激爽爽歪歪视频在线观看| 欧美性感艳星| 尾随美女入室| 最近视频中文字幕2019在线8| 成人一区二区视频在线观看| 天堂√8在线中文| 又爽又黄a免费视频| 精品久久久久久久久亚洲| 国产日本99.免费观看| ponron亚洲| 亚洲va在线va天堂va国产| 天天一区二区日本电影三级| 中国国产av一级| 亚洲丝袜综合中文字幕| 床上黄色一级片| 国产精品麻豆人妻色哟哟久久 | 成人三级黄色视频| 国产视频内射| 久久99蜜桃精品久久| 国产美女午夜福利| 亚洲激情五月婷婷啪啪| 亚洲欧美中文字幕日韩二区| 人体艺术视频欧美日本| 插阴视频在线观看视频| 一级黄色大片毛片| 一区二区三区免费毛片| 变态另类成人亚洲欧美熟女| 国模一区二区三区四区视频| 在线观看66精品国产| 亚洲七黄色美女视频| 国产成人一区二区在线| 黄色视频,在线免费观看| 午夜视频国产福利| 五月玫瑰六月丁香| 久久久精品大字幕| 少妇人妻一区二区三区视频| 免费看av在线观看网站| 亚洲欧美精品专区久久| 一级av片app| 日本与韩国留学比较| 老司机影院成人| 中文亚洲av片在线观看爽| 国产成人精品婷婷| 免费人成在线观看视频色| 亚洲精品色激情综合| 国产大屁股一区二区在线视频| 最好的美女福利视频网| 国产日本99.免费观看| 国内少妇人妻偷人精品xxx网站| 国产精品嫩草影院av在线观看| 欧美区成人在线视频| 久久6这里有精品| 搞女人的毛片| 搡老妇女老女人老熟妇| 九草在线视频观看| 天天躁日日操中文字幕| 亚洲经典国产精华液单| or卡值多少钱| 成人午夜精彩视频在线观看| 噜噜噜噜噜久久久久久91| 成人欧美大片| 91久久精品国产一区二区三区| 日韩一区二区视频免费看| 国产精品一区二区三区四区久久| 午夜精品一区二区三区免费看| 国产精品,欧美在线| 国产av一区在线观看免费| 男女做爰动态图高潮gif福利片| 亚洲人成网站在线播| 看非洲黑人一级黄片| 99久国产av精品| 91aial.com中文字幕在线观看| 国产亚洲欧美98| 欧美又色又爽又黄视频| 国产真实乱freesex| 99久久久亚洲精品蜜臀av| 99在线视频只有这里精品首页| 色哟哟哟哟哟哟| 国产精品嫩草影院av在线观看| 国产一级毛片七仙女欲春2| 亚洲va在线va天堂va国产| 美女脱内裤让男人舔精品视频 | 成人永久免费在线观看视频| 69人妻影院| 看免费成人av毛片| 久久午夜福利片| 国产精品一区二区在线观看99 | 丰满的人妻完整版| 亚洲美女搞黄在线观看| 国产蜜桃级精品一区二区三区| 久久精品国产鲁丝片午夜精品| 国产蜜桃级精品一区二区三区| 久久精品国产鲁丝片午夜精品| 日韩欧美一区二区三区在线观看| 一本精品99久久精品77| 久久中文看片网| 日本一本二区三区精品| 国产一区二区在线av高清观看| 成人午夜精彩视频在线观看| 18禁在线播放成人免费| 黄色一级大片看看| 日韩欧美精品免费久久| 国产免费一级a男人的天堂| 在线免费十八禁| 欧美一区二区精品小视频在线| 国产精品嫩草影院av在线观看| 成人毛片60女人毛片免费| 国产淫片久久久久久久久| 三级国产精品欧美在线观看| 热99re8久久精品国产| 国产av在哪里看| 国产单亲对白刺激| 国产一区二区在线观看日韩| 国产在视频线在精品| 99热只有精品国产| 国产伦精品一区二区三区四那| 国产视频首页在线观看| 麻豆成人av视频| 一区二区三区四区激情视频 | 午夜爱爱视频在线播放| 亚洲真实伦在线观看| 男人狂女人下面高潮的视频| 男女做爰动态图高潮gif福利片| av黄色大香蕉| 九色成人免费人妻av| 午夜免费男女啪啪视频观看| 国产精品女同一区二区软件| 成年版毛片免费区| 国产亚洲av嫩草精品影院| 天堂中文最新版在线下载 | 中文亚洲av片在线观看爽| 亚洲四区av| 我的老师免费观看完整版| 51国产日韩欧美| 蜜臀久久99精品久久宅男| 成人二区视频| www.色视频.com| 久久人妻av系列| 国产高清视频在线观看网站| 国产成人午夜福利电影在线观看| 免费大片18禁| 夫妻性生交免费视频一级片| 久久久久网色| 日日啪夜夜撸| 精品99又大又爽又粗少妇毛片| 国产伦精品一区二区三区视频9| 最近最新中文字幕大全电影3| АⅤ资源中文在线天堂| av在线亚洲专区| 69av精品久久久久久| 九九在线视频观看精品| 国产美女午夜福利| 哪个播放器可以免费观看大片| 亚洲不卡免费看| 国产精品,欧美在线| 欧美潮喷喷水| 国产黄色小视频在线观看| h日本视频在线播放| 禁无遮挡网站| 亚洲精品久久久久久婷婷小说 | 精品无人区乱码1区二区| 亚洲精品亚洲一区二区| 麻豆av噜噜一区二区三区| 日韩中字成人| 国产精品永久免费网站| 亚洲18禁久久av| 午夜免费男女啪啪视频观看| 嫩草影院新地址| 亚洲av二区三区四区| 久久午夜亚洲精品久久| 欧美+亚洲+日韩+国产| 夜夜夜夜夜久久久久| 国内揄拍国产精品人妻在线| 国产大屁股一区二区在线视频| 有码 亚洲区| 国产精品99久久久久久久久| 亚洲精品影视一区二区三区av| 身体一侧抽搐| a级毛色黄片| 亚洲欧洲国产日韩| 黄色欧美视频在线观看| 听说在线观看完整版免费高清| 色综合色国产| 午夜福利视频1000在线观看| 久久精品人妻少妇| 国产v大片淫在线免费观看| 久久久久久久久大av| 国产欧美日韩精品一区二区| 亚洲av一区综合| 在线a可以看的网站| 国产人妻一区二区三区在| 人人妻人人澡欧美一区二区| 欧洲精品卡2卡3卡4卡5卡区| 爱豆传媒免费全集在线观看| 国产成人午夜福利电影在线观看| 99国产精品一区二区蜜桃av| 亚洲第一区二区三区不卡| 一级黄片播放器| 国内揄拍国产精品人妻在线| 久久久精品大字幕| 欧美性感艳星| 一级黄色大片毛片| 日韩 亚洲 欧美在线| 深夜a级毛片| av黄色大香蕉| 成人特级av手机在线观看| 国产毛片a区久久久久| 日本欧美国产在线视频| 国产精品久久久久久亚洲av鲁大| 欧美成人精品欧美一级黄| 久久久久久久久久黄片| 亚洲三级黄色毛片| 日本免费a在线| 人体艺术视频欧美日本| 51国产日韩欧美| 男人舔女人下体高潮全视频| 国产色婷婷99| 日韩成人av中文字幕在线观看| 中文亚洲av片在线观看爽| 精品无人区乱码1区二区| 热99在线观看视频| 欧美潮喷喷水| 成人午夜高清在线视频| 人妻夜夜爽99麻豆av| 成人鲁丝片一二三区免费| 99久久中文字幕三级久久日本| 精品久久久久久久人妻蜜臀av| 欧美zozozo另类| 12—13女人毛片做爰片一| 99久国产av精品| 国产精品人妻久久久影院| 欧美+日韩+精品| 春色校园在线视频观看| 人人妻人人澡欧美一区二区| 精品人妻一区二区三区麻豆| or卡值多少钱| 国产精品久久电影中文字幕| 床上黄色一级片| 国产毛片a区久久久久| 久久久国产成人免费| 国产一区二区三区av在线 | 美女xxoo啪啪120秒动态图| 人体艺术视频欧美日本| a级毛色黄片| 免费电影在线观看免费观看| 亚洲欧美成人精品一区二区| 色播亚洲综合网| 精品人妻偷拍中文字幕| 欧美高清性xxxxhd video| 成年女人永久免费观看视频| 国内精品一区二区在线观看| 午夜福利视频1000在线观看| 村上凉子中文字幕在线| 丝袜喷水一区| 欧美性感艳星| 国产午夜福利久久久久久| 色视频www国产| 久久中文看片网| 伦精品一区二区三区| 美女内射精品一级片tv| 久久久久久九九精品二区国产| 99热这里只有精品一区| 国产av不卡久久| 国产精品乱码一区二三区的特点| av女优亚洲男人天堂| 色噜噜av男人的天堂激情| a级一级毛片免费在线观看| 六月丁香七月| 亚洲精品久久久久久婷婷小说 | 在线播放无遮挡| 午夜免费激情av| 亚洲国产精品sss在线观看| 国内精品久久久久精免费| 99国产精品一区二区蜜桃av| 天天躁夜夜躁狠狠久久av| 99久久人妻综合| 91久久精品国产一区二区三区| 在线a可以看的网站| 麻豆av噜噜一区二区三区| 国产高清视频在线观看网站| 国产毛片a区久久久久| 国产麻豆成人av免费视频| 亚洲综合色惰| 欧美激情国产日韩精品一区| av女优亚洲男人天堂| 亚洲美女视频黄频| 日韩成人伦理影院| 亚洲四区av| 少妇丰满av| 日韩欧美在线乱码| 国产精华一区二区三区| 日韩中字成人| 中文字幕av在线有码专区| 高清毛片免费观看视频网站| 日本色播在线视频| 免费一级毛片在线播放高清视频| 亚洲五月天丁香| 2022亚洲国产成人精品| 精品久久久久久久久久免费视频| 一区二区三区四区激情视频 | 蜜桃久久精品国产亚洲av| 激情 狠狠 欧美| 国产一级毛片七仙女欲春2| 中文字幕免费在线视频6| 日韩强制内射视频| 日本黄色视频三级网站网址| 中文字幕制服av| 久久久精品欧美日韩精品| 寂寞人妻少妇视频99o| 九九爱精品视频在线观看| 99九九线精品视频在线观看视频| 精品一区二区三区人妻视频| 亚洲美女搞黄在线观看| 欧美一区二区亚洲| 国产精品综合久久久久久久免费| 亚洲国产精品久久男人天堂| 一级毛片久久久久久久久女| ponron亚洲| 最近最新中文字幕大全电影3| 两个人视频免费观看高清| 波多野结衣高清无吗| 丝袜喷水一区| 少妇猛男粗大的猛烈进出视频 | 一本精品99久久精品77| 91在线精品国自产拍蜜月| 亚洲精品日韩在线中文字幕 | av在线天堂中文字幕|